Table 2.
Study completion and adherence to treatment
| Nifedipine (n=298) | Labetalol (n=295) | Methyldopa (n=301) | Absolute difference, nifedipine vs labetalol (95% CI) | Absolute difference, nifedipine vs methyldopa (95% CI) | Absolute difference, labetalol vs methyldopa (95% CI) | ||
|---|---|---|---|---|---|---|---|
| Median time from randomisation to start of treatment, min | 10 (0 to 55) | 10 (0 to 77) | 10 (0 to 45) | 0 (−1·7 to 1·7) | 0 (−1·7 to 1·7) | 0 (−1·7 to 1·7) | |
| Transferred to another site or delivered before 6 h | 8 (3%) | 9 (3%) | 8 (3%) | −0·4 (−3·1 to 2·3) | 0·03 (−2·6 to 2·6) | 0·4 (−2·3 to 3·1) | |
| Received at least one dose of allocated medication | 298 (100%) | 295 (100%) | 301 (100%) | .. | .. | .. | |
| Received a second dose of allocated medication | 131 (44%) | 142 (48%) | 0 | −4·1 (−12·1 to 3·9)* | .. | .. | |
| Median time received after randomisation, min | 85 (60 to 365) | 130 (60 to 370) | 0 | −45 (−78 to −12) | .. | .. | |
| Received a third dose of allocated medication | 45 (15%) | 64 (22%) | 0 | −6·6 (−12·8 to 0·4)† | .. | .. | |
| Median time received after randomisation, min | 175 (120 to 360) | 190 (125 to 330) | 0 | −15 (−66 to 36) | .. | .. | |
| Received another antihypertensive drug during the study period‡ | 2 (1%) | 9 (3%) | 56 (19%) | −2·4 (−4·6 to −0·2) | −17·9 (−22·4 to −13·4) | −15·6 (−20·4 to 10·7) | |
| Nifedipine§ | 0 | 8 (3%) | 47 (16%) | −2·7 (−4·5 to −0·9) | −15·6 (−19·7 to −11·5) | −12·9 (−17·4 to −8·4) | |
| Labetalol (orally)¶ | 1 (<1%) | 0 | 10 (3%) | 0·3 (−0·3 to 0·9) | −3·0 (−5·1 to −0·9) | −3·3 (−5·3 to −1·3) | |
| Labetalol (intravenously) | 0 | 1 (<1%) | 0 | −0·3 (−0·9 to 0·3) | .. | 0·3 (−0·3 to 0·9) | |
| Methyldopa | 1 (<1%) | 0 | 1 (<1%) | 0·3 (−0·3 to 0·9) | 0·003 (−0·9 to 0·9) | −0·3 (−0·9 to 0·3) | |
Data are median (range) or n (%), unless otherwise indicated. In the methyldopa group, one woman received a dose each of nifedipine and labetalol, one woman received a dose of nifedipine and an additional methyldopa dose, and four women received two doses of nifedipine.
*
p=0·01.
†
p=0·04.
‡
Nifedipine vs labetalol: p=0·04; nifedipine vs methyldopa: p<0·0001; labetalol vs methyldopa: p<0·0001.
§
Nifedipine vs labetalol: p=0·004; nifedipine vs methyldopa: p<0·0001; labetalol vs methyldopa: p=0·002.
¶
Nifedipine vs methyldopa: p=0·01; labetalol vs methyldopa: p=0·01.